|

18F-DCFpyL Clinical Trials

6 actively recruiting trials across 4 locations

No change since May 2026

Also known as: PSMA, PET, [F18]-Piflufolastat, Pylarify, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}ureido)-pentanedioic acid

Pipeline

Early 1: 1Phase 2: 3Phase 4: 1

Top Sponsors

  • National Cancer Institute (NCI)3
  • University of Wisconsin, Madison1
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • Brigham and Women's Hospital1

Indications

  • Cancer6
  • Prostate Cancer4
  • Biochemically Recurrent1
  • Metastatic Castration-Resistant Prostate Carcinoma1
  • Metastatic Castration-resistant Prostate Cancer1

Bethesda, Maryland3 trials

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

National Institutes of Health Clinical Center

Phase 2
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

National Institutes of Health Clinical Center

Phase 2
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

National Institutes of Health Clinical Center

Baltimore, Maryland1 trial

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

SKCCC at Johns Hopkins

Early 1

Boston, Massachusetts1 trial

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Dana Farber Cancer Institute

Phase 4

Madison, Wisconsin1 trial

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

University of Wisconsin School of Medicine and Public Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.